(Q43511123)

24 November 2017

0 references

0 references

Do statins cause cancer? A meta-analysis of large randomized clinical trials (English)

1 reference

24 November 2017

1 reference

Bjerre LM

1

1 reference

PubMed ID

11403756

24 November 2017

LeLorier J

series ordinal

2

1 reference

PubMed ID

11403756

24 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

American Journal of Medicine

24 November 2017

1 reference

24 November 2017

110

1 reference

24 November 2017

716-723

1 reference

24 November 2017

9

1 reference

State-of-the-art update and review: clinical trials of lipid-lowering agents

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Risk factor modification: rationale for management of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Carcinogenicity of lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Colon cancer and blood-cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

From the NIH: Cholesterol and noncardiovascular mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

The relationship of serum cholesterol to the incidence of cancer in Evans County, Georgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Serum total cholesterol and mortality in a Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol and mortality in New Zealand Maoris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Report of the Conference on Low Blood Cholesterol: Mortality Associations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Dietary lipids and the low blood cholesterol-cancer association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Assessing possible hazards of reducing serum cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Bias in meta-analytic research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Large-scale randomized evidence: large, simple trials and overviews of trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol, primary and secondary prevention, and all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

The practice of meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Meta-analysis: science or religion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Issues in comparisons between meta-analyses and large trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Can meta-analyses be trusted?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Meta-analysis: statistical alchemy for the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

"Large-scale randomized evidence: large, simple trials and overviews of trials": discussion. A clinician's perspective on meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Passive smoking, coronary heart disease, and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Serum cholesterol and cancer risk: an epidemiologic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Systematic review on the risk and benefit of different cholesterol-lowering interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol reduction yields clinical benefit. A new look at old data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol reduction and its impact on coronary artery disease and total mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900705-7

10.1016/S0002-9343(01)00705-7

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

11403756